Paul Lizzul

Paul Lizzul

Company: AnaptysBio

Job title: Chief Medical Officer


Spotlight on Imsidolimab (ANB019): An Anti-IL36 Receptor Monoclonal Antibody, in the Treatment of Generalized Pustular Psoriasis & Other Inflammatory Dermatoses 11:30 am

• Examining the IL36 signaling axis and its role in inflammatory skin disease and explore characterization of imsidolimab, a humanized anti-IL36 receptor monoclonal antibody • Summarizing AnaptysBio imsidolimab clinical development strategy in dermatology • Discussing the results of a phase 2 clinical trial of imsidolimab in subjects with active generalized pustular psoriasis (GPP) • Evaluating…Read more

day: Day 1 AM - Track 2

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.